William S Oetting

List of Publications by Year
in descending order

87	2,441	304743	233421
papers	citations	22 h-index	45 g-index

105	105	105	3318
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Whole Exome Sequencing Identifies Somatic Variants in an Oral Composite Hemangioendothelioma Characterized by YAP1-MAML2 Fusion. Head and Neck Pathology, 2022, 16, 849-856.	2.6	6
2	Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes. Nature Medicine, 2022, 28, 999-1005.	30.7	15
3	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. Journal of Clinical Pharmacology, 2021, 61, 1035-1044.	2.0	3
4	A custom capture sequence approach for oculocutaneous albinism identifies structural variant alleles at the OCA2 locus. Human Mutation, 2021, 42, 1239-1253.	2.5	7
5	A Multi-Marker Test for Analyzing Paired Genetic Data in Transplantation. Frontiers in Genetics, 2021, 12, 745773.	2.3	2
6	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1457-1465.	1.5	3
7	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. American Journal of Transplantation, 2019, 19, 2262-2273.	4.7	13
8	Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups. American Journal of Transplantation, 2019, 19, 2795-2804.	4.7	35
9	Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies. Transplantation, 2019, 103, 1131-1139.	1.0	17
10	Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A. Transplantation, 2019, 103, 1591-1602.	1.0	16
11	Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. Pharmacogenomics Journal, 2019, 19, 375-389.	2.0	11
12	NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1772-1779.	6.1	74
13	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics, 2018, 19, 175-184.	1.3	23
14	Genetics of acute rejection after kidney transplantation. Transplant International, 2018, 31, 263-277.	1.6	27
15	Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients. Clinical Transplantation, 2018, 32, e13436.	1.6	24
16	Tacrolimus Elimination in Four Patients With a <scp>CYP</scp>3A5*3/*3 <scp>CYP</scp>3A4*22/*22 Genotype Combination. Pharmacotherapy, 2018, 38, e46-e52.	2.6	17
17	Non-Coding Variation: The 2016 Annual Scientific Meeting of the Human Genome Variation Society. Human Mutation, 2017, 38, 460-463.	2.5	1
18	Concepts of Genomics in Kidney Transplantation. Current Transplantation Reports, 2017, 4, 116-123.	2.0	4

#	Article	IF	Citations
19	Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Medicine, 2015, 7, 90.	8.2	49
20	Differentially Expressed Gene Transcripts Using RNA Sequencing from the Blood of Immunosuppressed Kidney Allograft Recipients. PLoS ONE, 2015, 10, e0125045.	2.5	20
21	Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics, 2015, 16, 841-854.	1.3	31
22	Telomere Length of Recipients and Living Kidney Donors and Chronic Graft Dysfunction in Kidney Transplants. Transplantation, 2014, 97, 325-329.	1.0	18
23	Functional Fcgamma Receptor Polymorphisms Are Associated with Human Allergy. PLoS ONE, 2014, 9, e89196.	2.5	24
24	Transplant rejection and risk: in search of the genetic dark matter. Journal of Gastrointestinal and Liver Diseases, 2013, 22, 125-6.	0.9	1
25	Donor polymorphisms of tollâ€like receptor 4 associated with graft failure in liver transplant recipients. Liver Transplantation, 2012, 18, 1399-1405.	2.4	24
26	Validation of genetic variants associated with early acute rejection in kidney allograft transplantation. Clinical Transplantation, 2012, 26, 418-423.	1.6	9
27	Exome and genome analysis as a tool for disease identification and treatment: The 2011 human genome variation society scientific meeting. Human Mutation, 2012, 33, 586-590.	2.5	9
28	Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium. Transplantation, 2011, 91, 300-308.	1.0	151
29	Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort. Transplant International, 2011, 24, 1231-1238.	1.6	27
30	Sequencing the Human Genome: Gateway to Personalized Medicine or the New Eugenics?. Theology and Science, 2011, 9, 181-191.	0.3	0
31	Single-Nucleotide Polymorphisms, Acute Rejection, and Severity of Tubulitis in Kidney Transplantation, Accounting for Center-to-Center Variation. Transplantation, 2010, 90, 1401-1408.	1.0	37
32	The R402Q tyrosinase variant does not cause autosomal recessive ocular albinism. American Journal of Medical Genetics, Part A, 2009, 149A, 466-469.	1.2	35
33	Interpreting missense variants: comparing computational methods in human disease genesCDKN2A,MLH1,MSH2,MECP2, and tyrosinase (TYR). Human Mutation, 2007, 28, 683-693.	2.5	121
34	Pharmacogenetics of Mycophenolate Mofetil in Patients Undergoing Hematopoietic Cell Transplantation (HCT).. Blood, 2007, 110, 3010-3010.	1.4	0
35	Urinary Î²2-Microglobulin Is Associated With Acute Renal Allograft Rejection. American Journal of Kidney Diseases, 2006, 47, 898-904.	1.9	50
36	P gene mutations associated with oculocutaneous albinism type II (OCA2). Human Mutation, 2005, 25, 323-323.	2.5	97

#	Article	IF	Citations
37	Tyrosinase gene mutations in oculocutaneous albinismï¿½1 (OCA1): definition of the phenotype. Human Genetics, 2003, 113, 502-513.	3.8	144
38	Oculocutaneous Albinism Type 1: The Last 100â€ƒYears. Pigment Cell & Melanoma Research, 2003, 16, 307-311.	3.6	111
39	New insights into ocular albinism type 1 (OA1): Mutations and polymorphisms of the OA1 gene. Human Mutation, 2002, 19, 85-92.	2.5	44
40	Gene Expression Analysis. Pigment Cell & Melanoma Research, 2000, 13, 21-27.	3.6	1
41	The Tyrosinase Gene and Oculocutaneous Albinism Type 1 (OCA1): A Model for Understanding the Molecular Biology of Melanin Formation. Pigment Cell & Melanoma Research, 2000, 13, 320-325.	3.6	192
42	Microphthalmia-Associated Transcription Factor (MITF) Locus Lacks Linkage To Human Vitiligo Or Osteopetrosis: An Evaluation. Pigment Cell & Melanoma Research, 1999, 12, 187-192.	3.6	19
43	Three novel polymorphisms in the gene responsible for the Hermansky-Pudlak syndrome. Human Mutation, 1999, 13, 174-174.	2.5	0
44	Molecular basis of albinism: Mutations and polymorphisms of pigmentation genes associated with albinism. Human Mutation, 1999, 13, 99-115.	2.5	297
45	A novel splice site mutation (IVS17-2A>C) associated with Hermansky-Pudlak Syndrome. Human Mutation, 1999, 13, 506-506.	2.5	0
46	Multiplexed short tandem repeat polymorphisms of the Weber 8A set of markers using tailed primers and infrared fluorescence detection. Electrophoresis, 1998, 19, 3079-3083.	2.4	15
47	The clinical spectrum of albinism in humans. Trends in Molecular Medicine, 1996, 2, 330-335.	2.6	53
48	Detection of a Tsp509I polymorphism in the 3? UTR of the human tyrosinase related protein-1 (TYRP) gene. Human Genetics, 1995, 95, 247.	3.8	3
49	Analysis of tyrosinase gene mutations using direct automated infrared fluorescence DNA sequencing of amplified exons. Electrophoresis, 1994, 15, 159-164.	2.4	24
50	Analysis of Tyrosinase Mutations Associated With Tyrosinase-Related Oculocutaneous Albinism (OCAI). Pigment Cell & Melanoma Research, 1994, 7, 285-290.	3.6	31
51	Molecular basis of type I (tyrosinase-related) oculocutaneous albinism: Mutations and polymorphisms of the human tyrosinase gene. Human Mutation, 1993, 2, 1-6.	2.5	63
52	Purification and Characterization of Dopachrome Tautomerase (DT). Pigment Cell & Melanoma Research, 1990, 3, 32-35.	3.6	3
53	Molecular Basis of Type IA (Tyrosinase Negative) Oculocutaneous Albinism. Pigment Cell & Melanoma Research, 1990, 3, 249-253.	3.6	0
54	Comparative Anatomy and Physiology of Pigment Cells in Nonmammalian Tissues. , 0, , 11-59.		85

#	Article	IF	Citations
55	The Regulation of Melanin Formation. , 0, , 191-212.		6
56	Photobiology of Melanins. , 0, , 342-353.		4
57	Chemistry of Melanins. , 0, , 282-310.		34
58	Chemical, Pharmacologic, and Physical Agents Causing Hypomelanoses. , 0, , 669-685.		3
59	The Physical Properties of Melanins. , 0, , 311-341.		54
60	Topical Treatment of Pigmentary Disorders. , 0, , 1163-1174.		1
61	A History of the Science of Pigmentation. , 0, , 1-10.		15
62	Molecular Regulation of Melanin Formation: Melanosome Transporter Proteins. , 0, , 230-241.		1
63	Enzymology of Melanin Formation. , 0, , 261-281.		7
64	Toxicological Aspects of Melanin and Melanogenesis. , 0, , 354-394.		9
65	Regulation of Pigment Type Switching by Agouti, Melanocortin Signaling, Attractin, and Mahoganoid. , 0, , 395-409.		20
66	Human Pigmentation: Its Regulation by Ultraviolet Light and by Endocrine, Paracrine, and Autocrine Factors. , 0, , 410-420.		6
67	Paracrine Interactions of Melanocytes in Pigmentary Disorders. , 0, , 421-444.		5
68	The Genetics of Melanoma. , 0, , 472-488.		3
69	A More Precise Lexicon for Pigmentation, Pigmentary Disorders, andâ€œChromaticâ€•Abnormalities. , 0, , 497-503.		1
70	The Normal Color of Human Skin. , 0, , 504-520.		10
71	Mechanisms That Cause Abnormal Skin Color. , 0, , 521-537.		7
72	Genetic Hypomelanoses: Disorders Characterized By Congenital White Spotting - Piebaldism, Waardenburg Syndrome, and Related Genetic Disorders of Melanocyte Development - Clinical Aspects. , 0, , 539-550.		1

#	Article	IF	Citations
73	General Biology of Mammalian Pigmentation. , 0, , 61-90.		9
74	Genetic Hypomelanoses: Localized Hypopigmentation. , 0, , 636-656.		2
75	Inflammatory Hypomelanoses. , 0, , 699-704.		2
76	Hypomelanoses Associated with Melanocytic Neoplasia. , 0, , 705-724.		2
77	Extracutaneous Melanocytes. , 0, , 91-107.		8
78	Genetic Epidermal Syndromes: Disorders Characterized by Reticulated Hyperpigmentation. , 0, , 780-808.		2
79	Regulation of Melanoblast Migration and Differentiation. , 0, , 108-139.		17
80	Acquired Epidermal Hypermelanoses. , 0, , 907-978.		2
81	Mixed Epidermal and Dermal Hypermelanoses and Hyperchromias. , 0, , 1020-1025.		1
82	Drug-Induced or -Related Pigmentation. , 0, , 1026-1054.		2
83	Melanoblast Development and Associated Disorders. , 0, , 140-154.		4
84	Chemophototherapy of Pigmentary Disorders. , 0, , 1175-1182.		2
85	Biogenesis of Melanosomes. , 0, , 155-170.		12
86	Melanosome Trafficking and Transfer. , 0, , 171-180.		10
87	Melanosome Processing in Keratinocytes. , 0, , 181-190.		5